Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Apr 5;173(10):1639–1652. doi: 10.1111/bph.13465

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Aristolochic acid (AristA) enhances TREK‐1 and TREK‐2 currents, with apparent voltage‐dependence. (A) Time course plot showing an enhancement of human TREK‐1 current transiently expressed in tsA201 cells by AristA (100 μM). Each point is a 5 ms average of the difference current between that at −40 mV and that at −80 mV (see Methods for detailed description of voltage ramp protocol). (B) TREK‐1 currents evoked by ramp changes in voltage from −120 to +20 mV in control conditions and in the presence of 100 μM AristA. Inset shows percentage enhancement of TREK‐1 current by 100 μM AristA plotted as a function of voltage. (C) Time course plot showing an enhancement of human TREK‐2 current by AristA (100 μM). Inset shows percentage enhancement of TREK‐2 current by 100 μM AristA plotted as a function of voltage. (D) TREK‐2 currents evoked by ramp changes in voltage in control conditions and in the presence of 100 μM AristA.